Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Stage

Series A | Alive

About GammaMabs Pharma

GammaMabs Pharma is a biotechnology company developing a new monoclonal antibody targeting gynecological cancers, including ovarian cancer. Ovarian cancer is responsible for over 50 000 deaths every year in Europe and the United States. It has a poor prognosis as it is often diagnosed at an advanced stage due to a lack of systematic screening. Increasing resistance to traditional chemotherapy treatments justifies research into targeted therapeutic solutions, such as monoclonal antibodies.

GammaMabs Pharma Headquarter Location

France

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing GammaMabs Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

GammaMabs Pharma is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.